Exxon Teams with International Groups To Fight Malaria
BOSTON-ExxonMobil Corporation is teaming with the Harvard Malaria Initiative, Medicines for Malaria Venture, and Roll Back Malaria to develop new antimalarial drugs and malarial vaccines.
The groups will strengthen on-the-ground programs for malaria prevention and treatment in five sub-Saharan African countries where ExxonMobil has major production operation. Angola, Cameroon, Chad, Equatorial Guinea, and Nigeria will be receiving aid from the joint venture. The funding includes $1 million for the Harvard Malaria Initiative and $300,000 for Medicines for Malaria Venture. The groups want to increase awareness of the disease, strengthen research and prevention programs, and establish a public-private partnership for in-country programs.
Exxon has joined the group in part to encourage other private-sector companies to become involved. There are more people infected with the mosquito-borne disease in Africa today than any other time in recorded history. Malaria is a curable disease if promptly diagnosed. More than 40% of the world's population is at risk; however, the disease has been removed from most industrialized countries for decades through mass pesticide use.
In 2001, more than 300 million new cases will occur and more than one million people will die form the disease, the majority being young children.
Malaria also cripples the economies of developing countries through enormous cost in medical expenses and days of labor lost. It is estimated that each year, the direct and indirect cost of malaria drains $2 million from the economies of sub-Saharan African countries.
Information from www.businesswire.com
Newsletter
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
